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Background: Radiation dermatitis developing in patients receiving cetuximab concomitantly with radiotherapy for
locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is now recognized to have different
pathophysiological and clinical characteristics to the radiation dermatitis associated with radiotherapy or concomitant
chemotherapy and radiotherapy. Current grading tools were not designed to grade this type of radiation dermatitis;
their use may lead to misclassification of reactions and inappropriate management strategies, potentially
compromising cancer treatment.
Patients and methods: An advisory board of seven leading European specialists (three medical oncologists, three
radiation oncologists and a dermatologist) with extensive experience of the use of cetuximab plus radiotherapy
produced consensus guidelines for the grading and management of radiation dermatitis in patients receiving
cetuximab plus radiotherapy.
Results: Modifications to the current, commonly used National Cancer Institute—Common Terminology Criteria for
Adverse Events version 4.3 for grading radiation dermatitis were proposed. Updated management guidelines, building
on previously published guidelines from 2008, were also proposed.
Conclusions: The proposed revisions to the grading system and updated management guidelines described here
represent important developments toward the more appropriate grading and effective management of radiation
dermatitis in patients receiving cetuximab plus radiotherapy for LA SCCHN.
Key words: cetuximab, guidelines, locally advanced squamous cell carcinoma of the head and neck, management,
radiation dermatitis, radiotherapy
introduction
the need for revised grading criteria and updated
management guidelines
Radiotherapy plus the epidermal growth factor receptor
(EGFR) antibody cetuximab is now a standard treatment
approach for patients with locally advanced squamous cell
carcinoma of the head and neck (LA SCCHN) [1, 2]. Five-year
results of the pivotal phase III trial, which demonstrated that
adding cetuximab to radiotherapy had significant locoregional
control and survival benefits compared with radiotherapy
alone, reported that the improvement in survival seen with
cetuximab plus radiotherapy was maintained long term
(median 49.0 versus 29.3 months; 5-year survival rate 45.6%
versus 36.4%; hazard ratio 0.73; P = 0.018) [3].
Adding cetuximab to radiotherapy does not appear to unduly
increase the side-effects generally associated with radiotherapy
[1]. However, there have been reports of severe radiation
dermatitis-like skin reactions with cetuximab plus radiotherapy in
contrast to those seen with radiotherapy alone [4–9]. In the
pivotal phase III trial, there was no statistically significant
difference between the arms in the incidence of radiation
dermatitis (either all grades or grade ‡3), although there was an
increase of5% in the incidence of grade ‡3 radiation dermatitis
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in the cetuximab arm [1]. This is generally not higher than the
increase seen with concurrent chemotherapy and radiotherapy
[chemoradiotherapy (CRT)] compared with radiotherapy alone
[10, 11], although underreporting cannot be excluded. Outside
the setting of a randomized trial, data suggest that while there
may be a higher incidence of grade ‡3 radiation dermatitis in
patients receiving cetuximab plus radiotherapy compared with
those receiving concurrent CRT, the side-effects of CRT may have
a greater negative effect than cetuximab plus radiotherapy in
terms of patient symptoms and compliance with treatment [12]
(RM, personal communication). A single-center nonrandomized
comparison between patients receiving cetuximab plus
radiotherapy (n = 50) or CRT (n = 48) during the same time
period showed that the incidence of grade 3/4 dermatitis
(recorded by the same specialist nurse) was significantly higher
with radiotherapy plus cetuximab than with CRT (18.0% versus
2.1%; P = 0.014), although treatment compliance was
significantly higher for cetuximab plus radiotherapy compared
with CRT (noncompliance 12.0% versus 37.5%, respectively;
P = 0.003) (RM, personal communication).
In 2008, the conclusions of an advisory board convened to
discuss the management of skin reactions in patients receiving
EGFR inhibitors in combination with radiotherapy were
published [13]. Since these first guidelines were published,
there has been an increase in the understanding of the
pathophysiology of these skin reactions and a greater familiarity
among physicians with their clinical appearance. It is now
recognized that the skin reactions seen with cetuximab plus
radiotherapy have a different clinical appearance to those seen
with radiotherapy alone: they develop early, resolve rapidly and
often do not leave scarring. The National Cancer
Institute—Common Terminology Criteria for Adverse Events
(NCI–CTCAE) version 4.3 is an established, commonly used
tool for grading radiation dermatitis [14]. While it has proved
invaluable for the grading of dermatitis in patients receiving
radiotherapy with or without concurrent chemotherapy, the
NCI–CTCAE may be less appropriate for grading the type of
dermatitis seen in patients receiving cetuximab plus
radiotherapy and this may potentially compromise effective
treatment strategies. It is timely to consider modifications to
the current grading system and updated treatment guidelines to
help physicians to correctly grade and effectively manage
radiation dermatitis in patients receiving cetuximab plus
radiotherapy, thus optimizing treatment compliance and the
chances of a good clinical outcome.
This article reflects the findings from an advisory board
meeting held in February 2010, involving seven leading
European specialists (three medical oncologists, three radiation
oncologists and a dermatologist) with extensive experience of
the use of cetuximab and radiotherapy in SCCHN.
pathophysiological differences between dermatitis
observed following radiotherapy alone and
cetuximab plus radiotherapy
For patients receiving treatment with cetuximab plus
radiotherapy, the combination of skin responses induced by the
individual treatments leads to the characteristic reactions that
are reported with this treatment approach.
The primary effect of radiotherapy is on the proliferating
basal cells, the depletion of which leads to an alteration in the
normal turnover of skin cells. This effect is compounded by the
activity of radiotherapy on the differentiating functional strata,
comprising the less radiosensitive granular cells and anucleated
corneocytes. The result of these effects is a thinning of the
stratum granulosum, which is involved in the production of
lipids, natural moisturizing factor and keratin, all of which are
important factors in the prevention of transepidermal water
loss [15]. This thinning is visible as clumps of exfoliated
corneocytes (scales), characteristic of the dry desquamation
associated with a grade 1 radiation dermatitis reaction. When
the radiation dose is sufficiently high, an almost complete loss
of the basal cell layer, associated with a disruption of the
basement membrane and the failure of the barrier function,
leads to the exposure of the inflamed dermis and the moist
desquamation described for grade 2–3 reactions. While skin
necrosis or ulceration of the full-thickness dermis, as described
for grade 4 reactions, are possible side-effects of high-dose
radiotherapy, to our knowledge, such reactions have not been
reported in the acute phase with modern fractionated megavolt
radiotherapy.
The EGFR signaling pathway plays an integral part in the
development and maintenance of the skin and can have a
marked impact on the inflammatory and/or immune responses
of the skin [16]. As such, the finding that disruption of the
EGFR signaling pathway results in skin reactions is not
surprising [17]. The EGFR signaling pathway regulates the
survival, migration and proliferation of the various types of
skin cells [16]. It also has a major impact on the inflammatory/
immune reactions of the skin: activation of the pathway
appears to enhance the innate immune response and reduce the
proinflammatory functions of keratinocytes [16, 18–20].
Inhibition of the EGFR induces thinning of the functional
strata [21]; the development of xerosis [17]; skin inflammation,
particularly around the follicles; and alteration of the
expression of Toll-like receptors, thereby compromising the
synthesis of antimicrobial peptides [16] and favoring microbial
colonization and superinfection.
It is known that cetuximab enhances the sensitivity of tumor
cells to radiation [22], and it is likely that the concurrent
administration of cetuximab and radiotherapy results in some
degree of interplay between the effects of the individual agents
on the skin and an exacerbation of the reactions seen with the
individual agents. This interaction manifests as a more marked
xerosis, a more intense inflammatory response localized to the
subepidermis, a more obvious thinning of the epidermis and,
sometimes, necrosis of the superficial dermis and of the
epidermis (Figure 1). The reaction between cetuximab and
radiotherapy also induces the production of an inflammatory
exudation that mixes with the exfoliated corneocytes and dries
rapidly to form crusts (Figure 2A). These crusts can
compromise healing of the affected area in several ways. First,
they can be a cause of sustained microtrauma and are prone to
abrasion leading to bleeding and discomfort and/or pain
(Figure 2B). Secondly, they may harbor bacteria, thereby
potentially increasing the risk for superinfection (Figure 2C and
supplemental Figure S1, available at Annals of Oncology online),
an effect that may be exacerbated by the previously discussed
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Figure 1. Histological differences between the radiation dermatitis seen with radiotherapy alone (A) and that seen with cetuximab plus radiotherapy (B and
C). The epidermis is thin and devoid of rete ridges. The basal stratum is the most atrophic. (A) This shows a lichenoid tissue reaction (interface dermatitis),
a basophilic degeneration of the superficial dermis and dilated blood vessels. (B) In some areas, an interruption of the epidermis and limited necrosis of the
epidermis and of the superficial dermis (arrow) is associated with inflammatory lymphoplasmacellular and granulocytic infiltration of the subepidermis
(dotted arrow). (C) An immunostain for CD138 illustrates the plasmacellular population (arrows). The slide for cetuximab plus radiotherapy was obtained
from a patient undergoing treatment in the AlteRCC trial (Alternating Radiotherapy and Chemotherapy combined with Cetuximab) in which patients
received three cycles of cisplatin (20 mg/m2/day for 5 days) and 5-fluorouracil (200 mg/m2/day for 5 days) rapidly alternating with three split courses of
radiotherapy (up to 70 Gy) and concurrent weekly cetuximab [9]. Slides provided by Dr Rodolfo Brizio, Department of Histopathology, Santa Croce-Carle
General Hospital, Cuneo, Italy.
Figure 2. Examples of radiation dermatitis in three patients receiving cetuximab plus radiotherapy. (A) Modified grade 2 radiation dermatitis with non-
hemorrhagic crusts. (B and C) Two examples of modified grade 3 reactions that could be overclassified using the NCI–CTCAE grading system. In B,
bleeding is from <40% of the irradiated site and in C, hemorrhagic crusts cover <50% of the involved field. In C, hydrogel is being applied to the crusts.
NCI–CTCAE, National Cancer Institute—Common Terminology Criteria for Adverse Events.
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effects of EGFR inhibition on inflammatory/immune reactions.
In the case of severe reactions, superficial ulcerations with
crusty exudates are typically observed. In most cases, a small
number of basal stem cells are preserved, particularly around
the hair follicles, and this allows for the rapid regeneration of
the damaged skin.
The type of reaction observed following concurrent
administration of cetuximab and radiotherapy depends on the
degree of interaction between the two treatment modalities.
This results in varying degrees of a combination of the dry/
moist desquamation associated with radiotherapy and the
xerosis, inflammation and innate immune defense
deregulation associated with EGFR inhibition. It also appears
that the combination of the two treatment modalities alters
the timing of the onset of radiation dermatitis. In patients
receiving cetuximab plus radiotherapy, the onset of radiation
dermatitis may be earlier than that observed with
radiotherapy alone (week 1 or 2 compared with 3+ to 5+
weeks, respectively).
While the clinical appearance of reactions in patients
receiving cetuximab plus radiotherapy is of a more severe
dermatitis than is seen with radiotherapy alone, patients
generally recover within 1–2 weeks following the end of
treatment, even when there is crusting (Figure 2A). In addition,
there is generally no scarring following radiation dermatitis
with cetuximab plus radiotherapy (Figure 3C) [8]. To date, no
other long-term skin-related sequelae have been reported.
factors influencing the development of radiation
dermatitis
Although the majority of patients receiving radiotherapy will
develop dermatitis, a number of predisposing factors will
influence the severity of the reaction, independent of the dose
of radiotherapy. Intrinsic factors include the general skin
condition, nutritional status, chronoaging, photoaging and
comorbidities [23]. In addition, the stratum corneum in the
neck area is thinner than in other areas and so is more prone to
damage from skin reactions. Extrinsic factors include radiation
dose, energy and fractionation regimen [23] and the
combination of radiotherapy with chemotherapy [11]. These
intrinsic and extrinsic factors may provide the physician with
valuable pretreatment information regarding which patients
may be considered likely to require close monitoring for skin
reactions.
grading for radiation dermatitis in patients
receiving cetuximab plus radiotherapy
Radiation dermatitis associated with radiotherapy or CRT can
be effectively graded using the NCI–CTCAE version 4.3 [14].
However, given that the dermatitis associated with
radiotherapy administered in combination with cetuximab is
different from that seen with radiotherapy/CRT, the NCI–
CTCAE scale may be less appropriate for the grading of these
types of reactions. Specifically, there are two main issues with
the use of this scale in this setting. First, the distinction between
the gradings is unclear, particularly with regard to grade 3 and 4
reactions. Skin necrosis or ulceration of the full-thickness
dermis is included within the grade 4 reaction category of the
NCI–CTCAE. In patients receiving cetuximab plus
radiotherapy, the presence of the crusts makes a clinical
diagnosis of a true grade 4 reaction difficult to make without a
biopsy, which is not generally carried out in these patients.
Secondly, as the NCI–CTCAE scale was not designed to provide
grading for dermatitis associated with cetuximab plus
radiotherapy, its use may lead to a misclassification of grade 3
reactions to grade 4 reactions, particularly in the case of the
development of confluent crusty exudates. Such
misclassification may compromise the appropriate
management of skin reactions and, more importantly, may lead
to treatment delay or interruption, thereby potentially adversely
affecting outcome. The misclassification of reactions also
complicates the interpretation of intertrial comparisons of the
incidence of radiation dermatitis observed with different
treatment approaches.
Figure 3. Time course of radiation dermatitis in a patient receiving cetuximab and radiotherapy. (A) Modified grade 2 radiation dermatitis with non-
hemorrhagic crusts; (B) 1 week after completion of treatment; (C) 40 days after completion of treatment. Images are taken from one patient treated in the
AlteRCC trial (Alternating Radiotherapy and Chemotherapy combined with Cetuximab) in which patients received three cycles of cisplatin (20 mg/m2/day for 5
days) and 5-fluorouracil (200 mg/m2/day for 5 days) rapidly alternating with three split courses of radiotherapy (up to 70 Gy) and concurrent weekly cetuximab
[9]. On the appearance of dry desquamation and crusty exudation (A), hydrogel was applied to facilitate debridement. Ultrathin hydrocolloid dressings were
then applied to protect the skin from trauma and were changed twice weekly, or when indicated by excessive exudation.
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In view of these issues, the advisory board proposed a series
of modifications to the NCI–CTCAE version 4.3-defined
gradings with the aim of making the scale more applicable to
the radiation dermatitis seen with cetuximab plus radiotherapy.
The proposals for the revisions to each grade are detailed in
Table 1. The major modifications proposed are the inclusion of
the following features at different grades:
d Grades 2–4
d Crusting, the type (hemorrhagic or non-hemorrhagic) and
the extent of which are an important part of grading.
d The potential for local or systemic superinfection, which
will influence the selection of the most appropriate
management strategy. Superinfection can be identified by
the clinical appearance of the affected area [moist
desquamation and crusts, with yellowing (Figure 2C and
supplemental Figure S1, available at Annals of Oncology
online)] and by microbiological assessment (from swabs
of the area and blood tests).
d Grade 4
d The extent of spontaneous bleeding (Figure 2B).
According to the modified grading, extensive (>40% of the
involved site) spontaneous bleeding, rather than any level
of spontaneous bleeding, can be a feature of a grade 4
reaction. The authors recognize that it is difficult to
distinguish between true isolated spontaneous bleeding
and bleeding due to mechanical trauma [particularly
where there is crusting (Figure 2B)].
d Extensive confluent hemorrhagic crusting or ulceration
(>50% of the involved area) [5].
Physicians should continue to monitor patients for isolated
spontaneous bleeding and full-thickness necrosis, as the
development of these sequelae cannot be ruled out. Photographic
documentation of all grades of reactions is recommended.
management guidelines for radiation
dermatitis in patients receiving
cetuximab plus radiotherapy
Effective management should address both the epidermal
barrier disruption and the inflammatory and superinfection
components of the skin reaction to cetuximab plus
radiotherapy, to ensure treatment compliance and optimize
clinical outcome and medical resource use. While there is
currently no validated way of preventing the development of
radiation dermatitis, intervention at an early stage is crucial for
effective management. In addition, close collaboration with the
dermatologist at an early stage is advised, with this involvement
diminishing over time as physicians become more familiar with
the grading and management of the skin reactions. This
approach will optimize both effective management approaches
and the use of hospital resources.
The format of the management guidelines here does not
follow general NCI–CTCAE intervention rules, in terms of the
timing and route of treatment administration in accordance with
grade, e.g. grade 1, no treatment; grade 2, topical treatment;
grade 3, oral treatment; and grade 4, i.v. treatment. Instead, the
focus of these treatment guidelines concerns the impact of skin
reactions on the optimal delivery of anticancer treatment and
how such reactions can be managed so that anticancer treatment
compliance can be ensured. In general, patients with grade 1–3
reactions can be managed as outpatients, although this should be
decided on an individual patient basis. Initially, patients should
be monitored weekly by the management team for signs of skin
reactions, until the first sign of erythema, at which point
monitoring should become more frequent (at least twice
weekly). Patients developing severe early erythema should be
monitored closely throughout treatment. In cases of radiation
dermatitis of grade ‡3, the management team should evaluate
the need for daily assessment of the patient. Where daily
assessment is not possible, for instance, during weekends,
patients should be advised of what action to take should the
severity of a skin reaction increase.
The continuation of treatment with cetuximab depends on
the grade of radiation dermatitis observed. Cetuximab can
continue to be administered on a weekly basis to patients
developing up to grade 2 dermatitis and in those developing
grade 3 dermatitis who are being treated in a center
experienced in the management of these types of skin
reactions. It may be appropriate to consider a brief
interruption in the treatment of severe grade 3 dermatitis.
While grade 4 dermatitis is considered to be a rare event,
cetuximab, and/or other systemic anticancer treatments,
should be discontinued.
general measures
Patients should be provided with written information on how
to manage their skin reactions and the use of a nursing diary is
recommended. Skin hygiene is of paramount importance and
patients should be advised to keep the affected skin clean, to
wash their hands before touching the affected area and to use
clean towels. The affected area should be washed not more than
twice a day (once in the morning and once in the evening), using
pH 5 (pH skin neutral) soaps and/or showering oils for sensitive
skin, followed by moisturization with an unperfumed
moisturizer recommended for dry skin (supplemental Table S1,
available at Annals of Oncology online). There is no evidence of
any benefit of Aloe vera and there have been observations that it
may aggravate the reaction to treatment [25, 26]. Moisturizers
that contain urea (<3%) and/or have a high glycerol content are
recommended. Shaving with a sharp, disinfected wet razor
should be encouraged, where appropriate, to reduce the risk for
folliculitis, although care should be taken to avoid local trauma.
Patients should be advised to avoid sunbathing/sun exposure,
scratching and mechanical trauma in the affected area, and the
use of skin irritants, such as alcohol-based lotions and perfumes.
The debridement of crusts by a member of the management
team may help to reduce the risk for superinfection and bleeding
and may help with pain management. However, local trauma
should be avoided. Hydrogels, which can be used on their own
to keep crusts flexible and so reduce the risk for skin trauma and
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Table 1. Proposed modifications to the NCI–CTCAE v4.03 grading and grade-specific management strategies for patients developing radiation dermatitis during treatment with cetuximab plus radiotherapy
Grade of dermatitis associated with radiation-based therapy
Grade 1 Grade 2a Grade 3a Grade 4a
Definition: NCI–CTCAE,
v4.03 dermatitis radiation
Faint erythema or dry
desquamation
Moderate to brisk erythema;
patchy moist desquamation,
mostly confined to skin folds and
creases; moderate edema
Moist desquamation in
areas other than skin folds and
creases; bleeding induced by minor
trauma or abrasion
Life-threatening
consequences; skin necrosis or
ulceration of full-thickness dermis;
spontaneous bleeding from
involved site; skin graft indicated
Definition: Proposed
modification of NCI–CTCAE,
v4.03
Faint erythema or dry
desquamation
Moderate to brisk erythema
and/or dry desquamation; patchy
moist desquamation, or non-
hemorrhagic crusts mostly
confined to skin folds and creases
Moist desquamation or
hemorrhagic crusts; non-
hemorrhagic crusts other than in
skin folds and mostly confined to
skin folds and creases; bleeding
induced by minor trauma or
abrasion; superinfection requiring
oral antibiotics
Life-threatening
consequences; extensive confluent
hemorrhagic crusts or ulceration
(>50% of involved field); extensive
spontaneous bleeding from
involved site (>40% of the
involved site); skin necrosis or
ulceration of full-thickness dermis
or any size ulcer with extensive
destruction, tissue necrosis or
damage to muscle, bone or
supporting structures with or
without full-thickness skin lossb;
skin graft indicated; ulceration
associated with extensive
superinfection with i.v. antibiotics
indicated
General management
approaches
Reinforce general management
approachesc
Reinforce general management
approachesc
Reinforce general management
approachesc
Reinforce general management
approachesc
Grade-specific
management
approaches
d Weekly follow-up is
adequate, unless rapid
progression is noted
d Consider twice-weekly
assessments to monitor for
rapid change
A. Dry desquamation without
crusts:
d Consider glucocorticosteroid
cream or ointment for a
limited period (1–2 weeks)
d Topical antiseptics and
antibiotics at any sign
of superinfection
d Consider the use of topical
antiseptics and antibiotics
for the prevention of more
severe reactions
d Evaluate the need for
daily assessment
d Closely monitor for signs of
local or systemic infection
d For grade 3 reactions
occurring at <50 Gy,
consider brief
interruption in
treatment
A. Confluent moist
desquamation without
crusts:
d Topical antiseptic
d Consider interrupting
treatment with both
radiotherapy and
cetuximab. Cetuximab
should be interrupted
until the skin reaction has
resolved to at least grade 2
d In the case of severe
superinfection,
consider the use
of i.v. antibiotics if
unresponsive to oral
antibiotics
d Hospitalize the patient
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Table 1. (Continued)
Grade of dermatitis associated with radiation-based therapy
Grade 1 Grade 2a Grade 3a Grade 4a
B. Moist desquamation in skin
folds:
d Topical antiseptic
d Consider adding daily topical
glucocorticosteroid lotion to
reduce inflammation for a
limited period (1–2 weeks)
d Topical antibiotics active
against Staphylococcus aureus
at any sign of superinfection.
Consider systemic antibiotics
if superinfection becomes
more severe
d Topical eosin or soft zinc
preparations in the skin folds.
A thin layer of a soft zinc
preparation may be used in
skin folds, but should be
removed before treatment
with radiotherapy to avoid
radiation dosimetric
problems. Topical eosin in
skin folds or on erosive
lesions may also be a useful
treatment approach.
C. Dry desquamation with
isolated non-hemorrhagic
crusts:
d Topical antiseptic
d Consider adding daily topical
glucocorticosteroid lotion to
reduce inflammation for a
limited period (1–2 weeks)
d Topical antibiotics active
against S. aureus at any sign
of superinfection. Consider
systemic antibiotics if
superinfection becomes
more severe
d Consider adding daily
topical glucocorticosteroid
lotion to reduce
inflammation for a limited
period (1–2 weeks)
d Topical antibiotics active
against S. aureus at any
sign of superinfection
d If superinfection becomes
more severe, consider
the use of i.v. antibiotics
if unresponsive to
oral antibiotics
d Topical eosin or soft zinc
preparations in the skin
folds. A thin layer of a soft
zinc preparation may be
used in skin folds, but
should be removed before
treatment with
radiotherapy
to avoid radiation
dosimetric problems.
Topical eosin in skin folds
or on erosive lesions may
also be a useful treatment
approach
B. Confluent moist
desquamation with crusts:
d Topical antiseptic
d If superinfection
becomes more severe,
consider the use of i.v.
antibiotics if
unresponsive
to oral antibiotics
d Consider debridement
using hydrogels. Skin
trauma should be avoided
to prevent superinfection
A
n
n
a
ls
o
f
O
n
c
o
lo
g
y
o
rig
in
a
l
a
rtic
le
V
o
lu
m
e
2
2
|N
o
.
1
0
|O
c
to
b
e
r
2
0
1
1
d
o
i:1
0
.1
0
9
3
/a
n
n
o
n
c
/m
d
r1
3
9
|
2197
Table 1. (Continued)
Grade of dermatitis associated with radiation-based therapy
Grade 1 Grade 2a Grade 3a Grade 4a
d Topical eosin or soft zinc
preparations in the skin folds.
A thin layer of a soft zinc
preparation may be used in
skin folds but should be
removed before treatment
with radiotherapy to avoid
radiation dosimetric
problems
d Hydrogels can be used to keep
crusts flexible
d Consider debridement using
hydrogels (Figure 2C).
Skin trauma should be
avoided to prevent
superinfection
d If hydrocolloid dressings
are used, the thickness of
the dressing should be
taken into account for the
radiotherapy dosimetry.
Hydrofiber dressings can
be used after completion
of radiotherapy
Management team Radiation oncologist, medical
oncologist, nurse, dermatologistd
Radiation oncologist, medical
oncologist, nurse, dermatologistd
Radiation oncologist, medical
oncologist, nurse, dermatologistd
Involve a wound-healing
specialist in addition to the
radiation oncologist, medical
oncologist, nurse,
dermatologistd
See the supplemental Table S1 (available at Annals of Oncology online) for examples of suitable products.
aPossibility of local superinfection as indicated by the clinical appearance (moist desquamation and crusts, with yellowing) and by microbiological assessment (from swabs of the area and blood tests); suspected
systemic superinfection is indicated by the presence of at least two of the following four variables of systemic inflammatory response syndrome [24]: fever with a core temperature >38C or <36C, heart rate >90
beats per min, respiratory rate >20 breaths per min, leukocytosis (>12 · 109/l) or leukopenia (<4 · 109/l).
bSkin necrosis of full-thickness dermis is rarely seen with the recommended doses of cetuximab plus radiotherapy and this type of diagnosis should be based only on a biopsy of tissue from the involved site.
cSee ‘General Measures’ section in the text.
dEarly involvement of a dermatologist may facilitate effective management.
NCI–CTCAE, National Cancer Institute—Common Terminology Criteria for Adverse Events.
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pain (supplemental Table S1, available at Annals of Oncology
online), can also be used to facilitate debridement. Following
debridement, emollients can be used to moisturize the skin, and/
or hydrocolloid or hydrofiber dressings [27] can be used to
protect the skin from further trauma (supplemental Figure S1,
available at Annals of Oncology online). All dressings should be
transparent, so that any signs of superinfection can be observed
(supplemental Figure S1, available at Annals of Oncology online).
Also, consideration should be given to the need to remove
dressings before radiotherapy sessions if the type of dressing
significantly decreases the buildup effect of photon radiation.
Care should be taken to ensure that anything used on the skin, in
terms of dressings or creams, does not alter the dose of radiation
delivered to the skin [28]. Given the relatively high risk for
superinfection, the patient should be closely monitored for signs
of systemic inflammatory response and changes in the clinical
presentation of dermatitis. Where superinfection is suspected in
cases of dermatitis up to grade 2, local antiseptics and/or topical
antibiotics may be beneficial. The use of systemic antibiotics may
be considered if superinfection becomes more severe. Before the
initiation of any antibiotic treatment, culture data should, where
feasible, be obtained.
grade-specific management guidelines
Grade-specific management strategies are given in Table 1 and
examples of specific agents recommended for use in both general
and grade-specific management strategies are given in the
supplemental Table S1 (available at Annals of Oncology online).
While glucocorticosteroid creams or ointments can help in
the treatment of xerosis and reduce water loss from the skin,
there is no consensus regarding the efficacy of these agents in
the management of radiation dermatitis in patients receiving
cetuximab and radiotherapy [29, 30]. Indeed, some authors
suggest that topical glucocorticoids may potentiate the
cutaneous toxicity of EGFR inhibitors [31]. It is, therefore,
advisable to limit the use of glucocorticosteroids to short
periods of time (1–2 weeks). Short-term application of
glucocorticosteroid lotion (without alcohol) [31] may be useful
if moist desquamation (grade 2) starts to develop. Alternatively,
the combination of topical glucocorticosteroids plus local
antiseptics/antibiotics might be useful.
conclusions and future directions
Since the first regulatory approval of cetuximab plus
radiotherapy for the treatment of LA SCCHN in 2006, the
number of physicians using cetuximab in this setting has
increased steadily. The guidelines proposed here use our
current understanding of the pathophysiology and clinical
course of the radiation dermatitis reactions seen with
cetuximab plus radiotherapy to build on an existing grading
system [14] and earlier management guidelines [13]. The aims
of the proposed revisions to the grading system are to facilitate
discussions on the appropriate grading of radiation dermatitis
in patients receiving cetuximab and radiotherapy. The
consensus management guidelines will provide physicians with
a tool that can be used to ensure the effective treatment of these
reactions, thereby enabling patients to continue with scheduled
radiotherapy as planned and ensuring the efficient use of
medical resources. Specifically, the proposed adaptation of the
grading system may provide a more accurate way of identifying
of the highest grades of dermatitis. This adaptation has been
driven by the fact that the currently used grading system was
established before the introduction of treatment with a
combination of radiotherapy and targeted agents, and the
resulting change in the pathophysiology and distinctive clinical
pattern of the dermatitis observed with this treatment
approach. In addition to facilitating the correct grading of these
types of reactions, the adapted grading system may help in
determining the correct treatment approach for the most severe
grades of skin reactions.
It is recognized that the management of radiation
dermatitis associated with cetuximab plus radiotherapy is an
evolving area and it is likely that as our knowledge of the
pathophysiological mechanisms involved in these reactions
improves, alternative management approaches may be
considered. Current areas of interest for the management of
this type of radiation dermatitis include the use of calcineurin
inhibitors (pimecrolimus cream or tacrolimus ointment) for
tackling inflammation, the place of prophylaxis with a
glucocorticosteroid cream of low atrophogenic potential and
the use of prophylactic antibiotics, including doxycycline,
which has both antibiotic and immunomodulatory effects.
While a few of the trials that have investigated approaches
designed to prevent radiation dermatitis [26, 32–37] have
demonstrated some degree of efficacy, there are currently no
validated prevention strategies and this is an area that requires
continued investigation. Finally, as the use of cetuximab plus
radiotherapy in LA SCCHN continues to grow, physicians will
become more familiar with these reactions [38] and this in
itself may lead to the development of further management
options.
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